$0.18
0.56% yesterday
Nasdaq, Sep 27, 09:46 pm CET
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Aptevo Therapeutics Inc Stock price

$0.18
-0.19 51.55% 1M
-3.88 95.58% 6M
-7.78 97.75% YTD
-13.75 98.71% 1Y
-702.94 99.97% 3Y
-378.66 99.95% 5Y
-4,927.82 100.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.00 0.39%
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Key metrics

Market capitalization $1.70m
Enterprise Value $-1.34m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.06
P/B ratio (TTM) P/B ratio 0.16
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-25.95m
Free Cash Flow (TTM) Free Cash Flow $-24.30m
Cash position $8.07m
EPS (TTM) EPS $-47.12
Short interest 0.65%
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

Buy
100%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.44 0.44
38% 38%
-
-0.44 -0.44
38% 38%
-
- Selling and Administrative Expenses 11 11
11% 11%
-
- Research and Development Expense 14 14
20% 20%
-
-26 -26
17% 17%
-
- Depreciation and Amortization 0.44 0.44
38% 38%
-
EBIT (Operating Income) EBIT -26 -26
17% 17%
-
Net Profit -25 -25
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
9 days ago
SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 9,090,910 shares of its common stock or pre-funded warrants in lie...
Neutral
Accesswire
11 days ago
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to pur...
Neutral
Accesswire
about 2 months ago
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks* Outcomes also expected to identify recommended Phase 2 dose APVO436 renamed as mipletamig: Aptevo adopts new generic name fo...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 40
Founded 2016
Website www.aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today